• Explore /
  • Poster
  • / Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): a single-arm, open-label, multicenter, phase II study (CheckMate 172).

Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): a single-arm, open-label, multicenter, phase II study (CheckMate 172).

Abstract Poster

Authors

Paolo Antonio Ascierto

Paolo Antonio Ascierto

Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy

Paolo Antonio Ascierto , Lev V. Demidov , Claus Garbe , Paul Lorigan , Helen Gogas , Christoph Hoeller , John B. A. G. Haanen , Enrique Espinosa , Tormod Kyrre Guren , Eva Muñoz-Couselo , Andree Rorive , Piotr Rutkowski , Reinhard Dummer , Ana Carneiro , Geke Hospers , Frank Hermann , Joel Jiang , Dirk Schadendorf , Paul D. Nathan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02156804

Citation

J Clin Oncol 34, 2016 (suppl; abstr 9526)

DOI

10.1200/JCO.2016.34.15_suppl.9526

Abstract #

9526

Poster Bd #

131

Abstract Disclosures

Similar Posters

First Author: Dirk Schadendorf

First Author: Dirk Schadendorf

Poster

2015 ASCO Annual Meeting

Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.

Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.

First Author: Jeffrey S. Weber

First Author: Geoffrey Thomas Gibney